The PAR2 signal peptide prevents premature receptor cleavage and activation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 30 08 2019
accepted: 03 02 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 28 4 2020
Statut: epublish

Résumé

Unlike closely related GPCRs, protease-activated receptors (PAR1, PAR2, PAR3, and PAR4) have a predicted signal peptide at their N-terminus, which is encoded by a separate exon, suggesting that the signal peptides of PARs may serve an important and unique function, specific for PARs. In this report, we show that the PAR2 signal peptide, when fused to the N-terminus of IgG-Fc, effectively induced IgG-Fc secretion into culture medium, thus behaving like a classical signal peptide. The presence of PAR2 signal peptide has a strong effect on PAR2 cell surface expression, as deletion of the signal peptide (PAR2ΔSP) led to dramatic reduction of the cell surface expression and decreased responses to trypsin or the synthetic peptide ligand (SLIGKV). However, further deletion of the tethered ligand region (SLIGKV) at the N-terminus rescued the cell surface receptor expression and the response to the synthetic peptide ligand, suggesting that the signal peptide of PAR2 may be involved in preventing PAR2 from intracellular protease activation before reaching the cell surface. Supporting this hypothesis, an Arg36Ala mutation on PAR2ΔSP, which disabled the trypsin activation site, increased the receptor cell surface expression and the response to ligand stimulation. Similar effects were observed when PAR2ΔSP expressing cells were treated with protease inhibitors. Our findings indicated that there is a role of the PAR2 signal peptide in preventing the premature activation of PAR2 from intracellular protease cleavage before reaching the cells surface. The same mechanism may also apply to PAR1, PAR3, and PAR4.

Identifiants

pubmed: 32078628
doi: 10.1371/journal.pone.0222685
pii: PONE-D-19-23622
pmc: PMC7032737
doi:

Substances chimiques

Protease Inhibitors 0
Protein Sorting Signals 0
Receptor, PAR-1 0
Receptor, PAR-2 0
Receptors, Cell Surface 0
Endopeptidases EC 3.4.-
Trypsin EC 3.4.21.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0222685

Déclaration de conflit d'intérêts

Authors [BL, GL, JW, JD, CK, AH, LW, JT, TL, CL, SS] are employees of Janssen Research & Development, LLC. However, this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Pharmacol Rev. 2001 Jun;53(2):245-82
pubmed: 11356985
Elife. 2014 Jan 01;3:e01630
pubmed: 24596151
Mol Pharmacol. 2015 Nov;88(5):911-25
pubmed: 26349500
Cell. 2003 Feb 21;112(4):491-505
pubmed: 12600313
J Biol Chem. 2003 Aug 15;278(33):31024-32
pubmed: 12782636
J Cell Sci. 2002 Mar 15;115(Pt 6):1113-22
pubmed: 11884512
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13425-30
pubmed: 9811816
Cell. 2006 Feb 10;124(3):535-47
pubmed: 16469700
Mol Biol Cell. 2003 Nov;14(11):4427-36
pubmed: 14551254
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9557-9562
pubmed: 30181269
J Biol Chem. 1998 Dec 4;273(49):32373-6
pubmed: 9829963
Nature. 1998 Dec 17;396(6712):679-82
pubmed: 9872316
J Cell Biol. 1980 Dec;87(3 Pt 1):611-28
pubmed: 7462318
Annu Rev Cell Dev Biol. 2011;27:213-35
pubmed: 21721945
Eur J Cell Biol. 2012 Apr;91(4):294-9
pubmed: 21543132
Genes Dev. 1998 Mar 15;12(6):880-93
pubmed: 9512521
Nature. 2017 Jun 8;546(7657):259-264
pubmed: 28514451
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15219-24
pubmed: 21896768
Cell Cycle. 2006 Oct;5(20):2310-3
pubmed: 17102611
J Mol Endocrinol. 2014 Jun;52(3):T1-14
pubmed: 24868104
Curr Mol Pharmacol. 2017;10(4):311-317
pubmed: 28240192
Biochem Soc Trans. 2003 Dec;31(Pt 6):1253-6
pubmed: 14641036
J Biol Chem. 2012 Aug 3;287(32):27265-74
pubmed: 22689579
Prog Mol Biol Transl Sci. 2015;132:267-87
pubmed: 26055063
PLoS One. 2014 Feb 03;9(2):e87675
pubmed: 24498351
Cell Rep. 2014 Dec 24;9(6):2018-26
pubmed: 25533341
Annu Rev Cell Dev Biol. 1999;15:799-842
pubmed: 10611978
Mol Biol Cell. 2005 Jan;16(1):279-91
pubmed: 15496459
Mol Biol Cell. 2000 Aug;11(8):2821-31
pubmed: 10930472
J Pharmacol Exp Ther. 2016 May;357(2):394-414
pubmed: 26989142
Mol Pharmacol. 1995 Aug;48(2):316-25
pubmed: 7651365
J Biol Chem. 1995 Jun 23;270(25):14958-61
pubmed: 7797475
Dev Cell. 2005 Oct;9(4):545-54
pubmed: 16198296
Nature. 2011 Jul 27;475(7357):519-23
pubmed: 21796211
Proc Natl Acad Sci U S A. 1990 Dec;87(23):9378-82
pubmed: 2251280
Cell Cycle. 2004 Aug;3(8):986-9
pubmed: 15254406
Br J Pharmacol. 2010 Jan;159(1):237-51
pubmed: 20002095
Genes Dev. 2000 Sep 15;14(18):2330-43
pubmed: 10995389

Auteurs

Belinda Liu (B)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Grace Lee (G)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Jiejun Wu (J)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Janise Deming (J)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Chester Kuei (C)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Anthony Harrington (A)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Lien Wang (L)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Jennifer Towne (J)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Timothy Lovenberg (T)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Changlu Liu (C)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Siquan Sun (S)

Janssen Research & Development, LLC, San Diego, California, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH